 |
GET INVOLVED
EVENT DETAILS
DELEGATE INFORMATION
PARTNERS
WBR
|
|
|
Conference Agenda - Day One - Monday, October 6, 2008
| 7:30 |
Conference Registration & Card Swap Breakfast |
|
| 8:30 |
Welcome Address
Priya Pandian,
Executive Director, BioNetwork 2008 |
|
| 8:35 |
Chairperson’s Opening Remarks
Ronan Brown, Executive Director,
NovaQuest |
|
| 8:50 |
Leveraging Current Relationships To Gain Further Productivity
Eric Hagestad,
Senior Director Licensing, Bristol Myers Squibb
Katrine Bosley,
Vice President Strategic Operations, Adnexus |
|
| 9:30 |
PANEL: Effectively Managing An Alliance Through The Product Lifecycle
Jag Dosanjh, Vice President, Adult Vaccines, GlaxoSmithKline
Jeff Southerton,
Executive Director, Pfizer Global R&D, WW Business,
Development, Pfizer
Christian Pangratz,
Senior Director – Head of Strategic Alliances Business,
Development, Nektar Therapeutics |
|
| 10:10 |
Assets And Innovation: Making And Managing The Deal
Mark Barbato,
Vice President Alliance Management, Eli Lilly and Company
Jack Tupman,
Senior Director Corporate and Business Development, Eli Lilly and Company |
|
| 10:50 |
Refreshment Break & Networking Opportunity |
|
| 11:20 |
PANEL: Understanding Current Deal Trends To Position Yourself Attractively In Today's Market
Jim Schaeffer,
Executive Director, Licensing And External Research Merck,
Research Laboratories, West Coast, Merck
Ann Barry,
Senior Director Worldwide Business Development – CV/Athero, Pfizer
Gregg Davis,
Director, Worldwide Business Development, GlaxoSmithKline
Rekha Hemrajani,
Senior Director, Business Development, Exelixis
Markus Goebel,
Managing Director, Novartis Venture Funds |
|
| 12:00 |
Successfully Integrating Partner Companies After An Acquisition To Ensure Continued Productivity
Alex Scott,
Vice President Business Development, Eisai |
|
| 12:40 |
Lunch For All Conference Attendees |
|
| 1:40 |
PANEL: Finding The Right Time To Partner
Moderated by Mr. Joseph Dillon MBA, CLP, Senior Vice President and Head of Corporate Development, Services and Valuations, MattsonJack
Joy Thomas,
Vice President Corporate Development, BioSante
Jeremy Springhorn,
Vice President Business Development, Alexion
Katrine Bosley,
Vice President Strategic Operations, Adnexus
Richard Stover,
President and CEO, Pericor Therapeutics
Stephen Keane, President and COO, Femta Pharmaceuticals, Inc. |
|
| 2:20 |
Creating Value By Acquiring, Developing And Commercializing Products For Rare Disease With High Unmet Medical Need
Moderated by Mr. Joseph Dillon MBA, CLP, Senior Vice President and Head of Corporate Development, Services and Valuations, MattsonJack
Bryan Stuart,
Vice President Corporate Development and M&A, Ovation Pharmaceuticals |
|
| 3:00 |
Refreshment Break & Networking Opportunity |
|
| 3:30 |
Therapeutic Roundtables
Fred Chereau, Vice President and
General Manager, Cardiovascular Unit, Genzyme |
|
| 5:00 |
Cocktail Reception Sponsored By: Abbott |
|
Conference Agenda - Day Two - Tuesday, October 7, 2008
| 7:25 |
Conference Registration & Card Swap Breakfast |
|
| 8:25 |
Welcome Address
Priya Pandian,
Executive Director, BioNetwork 2008 |
|
| 8:30 |
Chairperson’s Opening Remarks |
|
| 8:45 |
Maximizing Your Partner’s Sales Force Capabilities To Optimize Commercialization Strategies
Michael Leonetti, Head of Healthcare Partnerships, Boehringer Ingelheim |
|
| 9:25 |
Market Access And Reimbursement Of Oncology Products: Lessons For The Future
Pierre Anhoury, Senior Vice President, Business Leader Europe, MattsonJack Europe |
|
| 10:05 |
Establishing A Strong Business Model For Pharmaceutical Companies In Europe And North America
Shabnam Kazmi, Vice President Business Development, Sanofi-Aventis |
|
| 10:45 |
Refreshment Break & Networking Opportunity |
|
| 11:15 |
PANEL: Understanding What To Provide To Big Pharma During The Partnership Inquiry
Jim Schaeffer, Executive Director, Licensing And External Research Merck Research Laboratories, West Coast, Merck
Gayle Kirkpatrick, Divisional Vice President, Scientific Assessment & Licensing Global Pharmaceutical Licensing & New Business Development, Abbott |
|
| 11:55 |
Business Focus Roundtables
Topic #1: Alternative Commercialization Partnering Models – Retaining Value - moderated by Ronan Brown, Executive Director, NovaQuest
Topic #2: Aligning IP Strategy With Business Development Plans
Topic #3: Understanding Key Valuation Challenges
Topic #4: Building Strong Relationships With Pharmaceutical Partners in Asia
Topic #5: Finding Alternative Financing Models For Biotech Companies - moderated by Teri Swift, Vice President Business Development, Xcovery |
|
| 1:25 |
Lunch For All Attendees |
|
| |
Concurrent Tracks |
| |
Track A |
Track B |
|
| 2:25 |
Inflammatory Disease Partnering Primer
Matt Meyer, General Counsel and Vice President Business Development and Licensing, Cerimon
Gunol Velicelebi, CEO, Calcimedica
François-Xavier Frapaise, CEO, Asphelia Pharmaceuticals |
CNS Disease Partnering Primer
Seth Goldblum, Vice President Business Development, BrainCells
Kevin Taylor, Vice President Business Development, Adolor
Ciara Kennedy, Senior Director, Business Development, Cypress
Bioscience |
|
| 3:05 |
Infectious Disease Partnering Primer
David Wurtman, Vice President Business Development, NexBio
Kirk Christoffersen, Senior Director Corporate Development, GlobeImmune
Robert S. Becker, Vice President Business Development, VaxInnate
Corporation |
Metabolic Disease Partnering Primer
Steven Damon, Vice President Business Development, Altea Therapeutics
William Abajian, Senior Executive Advisor, Global Strategic Alliances &
Business Development, Generex
John Mohr, Vice President Business Development, CV Therapeutics |
|
| 3:45 |
Refreshment Break & Networking Opportunity |
|
| 4:15 |
PANEL: Working With Government And Non-Governmental Organizations To Secure Non-Dilutive Capital
David Wurtman, Vice President Business Development, NexBio
Mauro Gibellini, Senior Vice President Corporate Affairs, Emergent BioSolutions |
|
| 4:55 |
Cocktail Reception For All Attendees |
|
Conference Agenda - Day Three - Wednesday, October 8, 2008
| 7:55 |
Conference Registration & Card Swap Breakfast |
|
| 8:55 |
Welcome Address
Priya Pandian,
Executive Director, BioNetwork 2008 |
|
| 9:00 |
Chairperson’s Opening Remarks
Jeffrey Totten, Vice President, Dean & Company |
|
| 9:15 |
Best Practices In Alliance Management: Case Study With
Roche And Ipsen
Jacques-Pierre Moreau, Executive Vice-President, Chief Scientific
Officer, Ipsen Group
Satbir Kaur, Global Alliance Director, Pharma Partnering Licensing
& Alliance Management Hoffmann, L.Hoffman-La Roche Ltd. |
|
| 9:55 |
PANEL: The Impact Of Personalized Medicine
Albine Martin, Vice President Strategic Alliances and Licensing, Compugen USA Inc
Meeta Patnaik, Senior Vice President, Predictive Diagnostic
Development, PGxHealth
Thomas Metcalfe, Head, Personalized HealthCare Portfolio,
L.Hoffman-La Roche Ltd.
Jack DeForrest, Vice President Technology Licensing, Medical Diagnostics, GE Healthcare |
|
| 10:35 |
PANEL: Preparing Your Company’s Capabilities For Future In-
Licensing Opportunities
Martin Reeves, Vice President Business Development and Strategic
Planning, Cephalon
Mark Wiggins, Head of Business Development, Biogen Idec
Lauren Miller, Director of Licensing, Bausch & Lomb Incorporated
Robert Ward, Vice President Business Development and Alliance
Management, NPS Pharmaceuticals |
|
| 11:15 |
Refreshment Break & Networking Opportunity |
|
| 11:45 |
PANEL: Evaluating The Sustainability Of The Specialty Pharma
Model
Jason Levin, Vice President Corporate Development, Jazz
Pharmaceuticals
Woody Bryan, Vice President Business Development, Licensing and
Project Management, Supernus Pharmaceuticals, Inc
Vikram Seoni, Vice President Business Development, Endo
Pharmaceuticals |
|
| 12:25 |
Lunch For All Attendees |
|
| 1:25 |
Exploring The Beauty Of Early-Stage Drug Candidates
Nils P. Debus, Senior Director, Global Business Development, Bayer
HealthCare Pharmaceuticals |
|
| 2:05 |
PANEL: The Environment In The Developing Biotech Arenas Of
Asia Pacific And What Business Models Work
Paul Kinnon, CEO, Zygem
Paul D’Sylva, CEO, Commonwealth Biotechnologies, Inc.
Mark Stuart, CEO, WaikatoLink Limited |
|
| 2:45 |
Conclusion Of BioNetwork 2008 |
|
|
|
|
|
